My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

14.81 -0.33 (-2.18%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 10, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

February 14, 2023

From Janux Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 09, 2023

Via Benzinga

Janux Therapeutics's Return On Capital Employed Overview ↗

December 22, 2022

Via Benzinga

Why Janux Therapeutics Shares Rose 33.1% This Week ↗

October 22, 2022

The clinical-stage biotech company just began its first clinical trial.

Via The Motley Fool

Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 01, 2023

Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit...

Via Benzinga

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

December 27, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present at Upcoming Investor Conferences in November

November 22, 2022

From Janux Therapeutics, Inc.

Via Business Wire

7 Short-Squeeze Stocks for Bold Contrarians to Consider ↗

November 21, 2022

While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.

Via InvestorPlace

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 10, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

October 12, 2022

From Janux Therapeutics, Inc.

Via Business Wire

7 Short-Squeeze Stocks to Buy for Contrarian Investors ↗

October 12, 2022

The pessimists may have bitten off more than they can chew for these intriguing contrarian market ideas.

Via InvestorPlace

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

September 23, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Janux Therapeutics Appoints Winston Kung to Board of Directors

September 22, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗

September 28, 2022

Gainers

Via Benzinga

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

August 31, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗

August 25, 2022

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.

Via Benzinga

Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday ↗

August 25, 2022

U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 09, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session ↗

June 24, 2022

Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.

Via Benzinga

Looking Into Janux Therapeutics's Return On Capital Employed ↗

June 13, 2022

According to Benzinga Pro data, during Q1, Janux Therapeutics (NASDAQ:JANX) posted sales of $1.59 million. Earnings were up 0.04%, but Janux Therapeutics still reported an overall loss of $13.41...

Via Benzinga

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

June 02, 2022

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

May 31, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

May 10, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

April 26, 2022

From Janux Therapeutics

Via Business Wire

Janux Therapeutics's Return On Capital Employed Overview ↗

March 21, 2022

Janux Therapeutics (NASDAQ:JANX) brought in sales totaling $1.62 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 24.61%, resulting in a...

Via Benzinga

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 18, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

January 05, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

November 09, 2021

From Janux Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.